Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Myocardial Infarction

Myocardial Infarction

Part of Myocardial ischemia

57 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Myocardial Infarction

139 trials tracked for Myocardial Infarction: 55 in phase 3 or 4 and 20 with published results. The most-cited published study has 2995 citations.

139Trials tracked
55Phase 3 & 4
0Recruiting
20With published results
Phase distribution
Phase 4 20 Phase 3 35 Phase 2 22 Other / NA 62
  1. Phase 3 Colchicine Cardiovascular Outcomes Trial (COLCOT) Completed · 2,995 cited
  2. Phase 3 Secondary Prevention of Cardiovascular Disease in the Elderly Trial Completed · 318 cited
  3. Phase 3 Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3) Completed · 295 cited
  4. Phase 3 Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction Completed · 295 cited
  5. Phase 3 Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack. Completed · 275 cited
  6. Phase 3 EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) Completed · 268 cited
Show 44 more trials
  1. Phase 4 Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction Completed · 184 cited
  2. Phase 3 Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging Completed · 170 cited
  3. Phase 4 INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure Completed · 131 cited
  4. Phase 3 Insulin Resistance Intervention After Stroke Trial Completed · 108 cited
  5. Phase 4 Subclinical Cardiovascular Disease in Psoriatic Disease Completed · 96 cited
  6. Phase 3 Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Completed · 58 cited
  7. Phase 4 STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction Completed · 54 cited
  8. Phase 3 Glutamate for Metabolic Intervention in Coronary Surgery Completed · 46 cited
  9. Phase 3 Trial to Assess Chelation Therapy 2 Completed · 26 cited
  10. Phase 4 Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor Completed · 22 cited
  11. Phase 4 Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus Completed · 19 cited
  12. Phase 3 Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI Completed · 16 cited
  13. Phase 3 Myocardial Ischemia and Transfusion Completed · 11 cited
  14. Phase 3 STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction Completed · 7 cited
  15. Phase 4 Alirocumab in Patients With Acute Myocardial Infarction Completed
  16. Phase 4 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction Completed
  17. Phase 4 Vorapaxar on Thrombin Generation and Coagulability Completed
  18. Phase 4 Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization Completed
  19. Phase 4 CES1 Crossover Trial of Clopidogrel and Ticagrelor Completed
  20. Phase 4 Effects of N-acetylcysteine on Low T3 Syndrome Completed
  21. Phase 4 Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients Completed
  22. Phase 4 APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3 Completed
  23. Phase 4 Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction Completed
  24. Phase 4 Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes Completed
  25. Phase 4 Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction Completed
  26. Phase 4 A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI) Completed
  27. Phase 4 Pilot Study of Edaravone to Treat Acute Myocardial Infarction Completed
  28. Phase 4 Aspirin Dose and Atherosclerosis in Patients With Heart Disease Completed
  29. Phase 3 Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI Completed
  30. Phase 3 SPECTACL: SPECTroscopic Assessment of Coronary Lipid Completed
  31. Phase 3 Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors Completed
  32. Phase 3 Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease Completed
  33. Phase 3 Myocardial Ischemia and Transfusion Pilot Completed
  34. Phase 3 Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial Completed
  35. Phase 3 Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial Completed
  36. Phase 3 Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) Completed
  37. Phase 3 Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography Completed
  38. Phase 3 Occluded Artery Trial (OAT) Completed
  39. Phase 3 IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium. Completed
  40. Phase 3 IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103) Completed
  41. Phase 3 Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) Completed
  42. Phase 3 An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome Completed
  43. Phase 3 Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Completed
  44. Phase 3 Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer Completed

Showing the 50 most-cited and recently-updated of 139 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Myocardial Infarction: what the trials found

Pharmacological management of myocardial infarction includes several agents with established profiles. Tenecteplase was associated with significantly higher rates of successful reperfusion compared to the comparator 9. Ticagrelor demonstrated no significant difference in TIMI flow grade or ST-segment resolution compared to its comparator 18, while alirocumab showed a significant reduction in LDL cholesterol but did not significantly impact hsCRP levels 16.

Antiplatelet and other pharmacological interventions show varied results. Prasugrel was associated with lower maximal platelet aggregation 10, whereas Vorapaxar did not show a statistically significant difference in maximal platelet aggregation in patients with DM 11 or in response to specific activating peptides 14. Clopidogrel showed a significant change in maximal platelet aggregation compared to the baseline, while Ticagrelor did not differ significantly from its comparator in this metric 12. Aspirin and/or Atorvastatin were associated with changes in inflammatory transcripts 8, and Aspirin alone was associated with changes in nitric oxide formation 22.

Other interventions include Exenatide, which showed significant improvements in steady-state glucose values and time to steady state 19. N-acetylcysteine was evaluated regarding serum T3 levels 17.

Recent results — preliminary, needs further review

  • • Physical activity was associated with significantly improved self-reported physical function scores (p<0.001), but no significant difference in cardiovascular events or non-cardiovascular mortality (p=0.49, p=0.85) 1. • IVL with Shockwave C2+ 2Hz Coronary IVL Catheter showed a 98.6% rate of freedom from MACE within 30 days and a 97.9% procedural success rate 4. • Ferric carboxymaltose was associated with a decrease in the Wall Motion Score Index 5. • Eplerenone significantly reduced the first event of cardiovascular mortality, re-hospitalization, or extended hospital stay due to heart failure (p<0.0001), though it did not significantly impact overall cardiovascular mortality or diagnosis of heart failure 6.

For the clinician treating this condition

  • Tenecteplase is associated with superior reperfusion rates compared to alternatives in acute settings 9.
  • Eplerenone significantly reduces composite outcomes including re-hospitalization and extended stay for heart failure (p<0.0001) 6.
  • Physical activity improves patient-reported physical function scores post-MI 1.

AI synthesis of 15 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
SGLT2 inhibitors and GLP-1 receptor agonists show similar MACE reduction in type 2 diabetes
Diabetes & Endocrinology Meta-analysis
SGLT2 inhibitors and GLP-1 receptor agonists show similar MACE reduction in type 2 diabetes Trial shows similar heart benefits for two diabetes medications
This systematic review and network meta-analysis compared SGLT2 inhibitors and GLP-1 receptor agonists for major adverse cardiovascular even…
Two common types of diabetes drugs both show significant reductions in major heart events for patients with a history of heart attacks.
Frontiers Jul 29, 2026
Behavioral and metabolic factors characterize a distinct premature atherosclerosis phenotype in Chinese patients
Cardiology Meta-analysis
Behavioral and metabolic factors characterize a distinct premature atherosclerosis phenotype in Chinese patients Smoking and Metabolic Factors Linked to Heart Attacks in China
This systematic review of 317 observational studies maps risk factors for premature myocardial infarction (PMI) in China. The synthesis iden…
A large review of 317 studies identifies specific behavioral and metabolic risk factors for heart attacks among Chinese patients.
Frontiers Jul 28, 2026
Percutaneous transcatheter closure using an Amplatzer Muscular VSD Occluder treats left ventricular pseudoaneurysm
Cardiology Guideline
Percutaneous transcatheter closure using an Amplatzer Muscular VSD Occluder treats left ventricular pseudoaneurysm Transcatheter Closure Shows Promise for Heart Failure Patients
This case report describes a 75-year-old male with heart failure and a left ventricular pseudoaneurysm successfully treated via percutaneous…
A new procedure using a transcatheter occluder may offer a safe way to treat heart failure caused by a specific heart wall defect.
Frontiers Jul 23, 2026
Magnetocardiography identifies infarction features in MINOCA patients with normal ECG findings
Cardiology Guideline
Magnetocardiography identifies infarction features in MINOCA patients with normal ECG findings Magnetocardiography shows heart damage when standard tests are normal
This case series explores the use of magnetocardiography (MCG) for identifying myocardial infarction in patients with non-ST-segment elevati…
New imaging may help identify heart attacks in patients whose standard EKG results appear normal, offering a potential new tool for clearer …
Frontiers Jul 16, 2026
21% hypertension prevalence in transgender adults: meta-analysis of cardiovascular morbidities
Cardiology Meta-analysis
21% hypertension prevalence in transgender adults: meta-analysis of cardiovascular morbidities Transgender adults face high rates of heart disease
This meta-analysis of observational studies reports pooled prevalence of major cardiovascular morbidities among transgender adults aged ≥18 …
One in five transgender adults has high blood pressure, and many have heart disease, a new analysis finds.
Frontiers Jul 15, 2026
Macrophage migration inhibitory factor serves as a potential biomarker and therapeutic target for atrial fibrillation
Cardiology Sys. Review
Macrophage migration inhibitory factor serves as a potential biomarker and therapeutic target for atrial fibrillation Protein levels may predict heart failure and stroke risks
This systematic review synthesizes evidence regarding macrophage migration inhibitory factor (MIF) in the context of atrial fibrillation and…
A specific protein called MIF is linked to heart damage and can help doctors predict serious complications like stroke or heart failure.
Frontiers Jul 9, 2026
Finerenone reduces mortality and heart failure risk (HR 0.644) in post-AMI patients
Cardiology RCT
Finerenone reduces mortality and heart failure risk (HR 0.644) in post-AMI patients Finerenone may lower heart failure risk after heart attack
This retrospective cohort study of 1,012 adult patients with AMI found that finerenone initiation within 6 months was associated with a lowe…
A new look at real-world data suggests the drug finerenone could protect hearts and kidneys in patients following a heart attack.
medRxiv Jun 29, 2026
Immune-stromal imbalance drives heart failure after myocardial infarction, systematic review finds
Cardiology Sys. Review
Immune-stromal imbalance drives heart failure after myocardial infarction, systematic review finds Immune cell balance determines if heart tissue heals or fails
This systematic review maps the bidirectional regulatory network between immune cells and cardiac stromal cells after myocardial infarction.…
A new map of how immune cells talk to heart tissue helps explain why some hearts heal after a heart attack while others develop failure.
Frontiers Jun 18, 2026
Tocilizumab shows early anti-inflammatory effects but no significant clinical benefit in STEMI or NSTEMI
Cardiology Meta-analysis
Tocilizumab shows early anti-inflammatory effects but no significant clinical benefit in STEMI or NSTEMI Tocilizumab shows early signs of heart protection in heart attacks
This meta-analysis of randomized controlled trials evaluated tocilizumab for patients with STEMI and NSTEMI. While the intervention showed a…
A new review looks at how the drug tocilizumab affects patients with heart attacks, showing some early signs of reduced inflammation.
Jun 15, 2026
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
Drug Pipeline Guideline
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Frontiers Jun 13, 2026
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
Cardiology Sys. Review
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings SGLT2 inhibitors show promise for heart failure and diabetes
This narrative review examines the cardiovascular and metabolic effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin. T…
New evidence shows how SGLT2 inhibitors may protect the heart and manage risks for patients with type 2 diabetes and heart failure.
Frontiers Jun 9, 2026
Current literature lacks research on myocardial infarction warning signs within transgender and gender diverse populations in the United States
Primary Care & Family Medicine Sys. Review
Current literature lacks research on myocardial infarction warning signs within transgender and gender diverse populations in the United States No clear guide exists for transgender heart attack warning signs in the United States
A brief review highlights a critical gap in understanding heart attack symptoms for transgender and gender diverse individuals. More researc…
A review found no current research on heart attack warning signs for transgender people, leaving them without standard heart health educatio…
Frontiers Jun 5, 2026

Research across Myocardial ischemia

Related studies from across the Myocardial ischemia family.

Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patients
Cardiology Meta-analysis
Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patients Ticagrelor Shows Lower Mortality Risk Than Clopidogrel for Heart Patients
This meta-analysis of 31,729 adult STEMI patients post-PCI found that ticagrelor significantly reduced all-cause mortality (OR = 0.64) and m…
A large analysis of over 31,000 patients suggests ticagrelor may lower mortality and heart attack risks compared to clopidogrel after a hear…
NEJM Jul 26, 2026
Transvalvular microaxial flow pump plus PCI does not reduce infarct size in anterior STEMI
Cardiology RCT
Transvalvular microaxial flow pump plus PCI does not reduce infarct size in anterior STEMI Trial shows microaxial flow pump does not reduce heart damage
This randomized controlled trial of 527 adults with acute anterior STEMI found that LV unloading with a transvalvular microaxial flow pump f…
A clinical trial found that using a transvalvular microaxial flow pump before heart surgery did not reduce the size of heart tissue damage.
Jul 9, 2026
Staged revascularization shows no significant difference versus immediate revascularization for major adverse cardiovascular events in STEMI and MVD patients
Cardiology Meta-analysis
Staged revascularization shows no significant difference versus immediate revascularization for major adverse cardiovascular events in STEMI and MVD patients Timing of heart surgery does not change survival for a specific heart attack group
This meta-analysis reviewed 5077 patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease comparing …
A large review found that waiting for staged heart surgery did not improve survival or reduce heart attacks compared to immediate surgery fo…
Jun 1, 2026
Complete revascularization shows high probability of benefit for NSTEMI patients with multivessel disease
Cardiology RCT
Complete revascularization shows high probability of benefit for NSTEMI patients with multivessel disease Complete revascularization shows high probability of benefit for NSTEMI patients with multivessel disease
This Bayesian re-analysis of a randomized trial evaluated complete versus culprit-only revascularization in patients with non-ST-elevation m…
A Bayesian re-analysis suggests complete revascularization offers a high probability of clinically meaningful benefit compared to treating o…
Jun 1, 2026
Prehospital unfractionated heparin bolus improved TIMI flow in STEMI without increasing bleeding risk
Cardiology RCT
Prehospital unfractionated heparin bolus improved TIMI flow in STEMI without increasing bleeding risk Pretreatment with UFH improves artery flow for STEMI patients without extra bleeding risk
This single-center randomized trial evaluated pretreatment with unfractionated heparin in patients with ST-segment-elevation myocardial infa…
Giving unfractionated heparin early at first medical contact improved artery flow in heart attack patients without increasing bleeding risk.
May 19, 2026
Case report and review of literature on acute NSTEMI after fluorescein angiography in a 76-year-old woman
Ophthalmology Sys. Review
Case report and review of literature on acute NSTEMI after fluorescein angiography in a 76-year-old woman Rare heart attack possible after fluorescein angiography in older adults with heart disease
This case report and review of the literature describes a 76-year-old woman with hypertension, hyperlipidemia, and type 2 diabetes mellitus …
A 76-year-old woman with heart disease had a heart attack shortly after a dye test, highlighting rare risks.
Frontiers May 18, 2026
Meta-analysis shows no significant difference between immediate and staged revascularization for STEMI with multivessel disease
Cardiology Meta-analysis
Meta-analysis shows no significant difference between immediate and staged revascularization for STEMI with multivessel disease Immediate heart procedure shows no major benefit over staged approach for heart attack patients
This systematic review and meta-analysis evaluated patients with ST-elevation myocardial infarction and multivessel disease undergoing immed…
A large review of heart attack patients with multiple blocked arteries found that doing the full procedure right away did not lower the risk…
May 15, 2026
Narrative review discusses iron-dependent ferroptosis in cardiac microvascular endothelial cells during myocardial ischemia-reperfusion
Cardiology Sys. Review
Narrative review discusses iron-dependent ferroptosis in cardiac microvascular endothelial cells during myocardial ischemia-reperfusion Iron overload damages heart vessels and blocks blood flow after a heart attack
This narrative review examines the role of iron-dependent ferroptosis and dysregulated iron homeostasis in cardiac microvascular endothelial…
Doctors now see that iron overload inside heart cells blocks blood flow even when major arteries are open
Frontiers May 7, 2026
Family history, prior arrhythmia, and anterior infarct location independently raise risk of ventricular fibrillation in STEMI patients
Cardiology Meta-analysis
Family history, prior arrhythmia, and anterior infarct location independently raise risk of ventricular fibrillation in STEMI patients Family history and heart attack location raise risk of dangerous heart rhythms in young patients
This meta-analysis of 1807 cases and 2923 controls confirms that family history of sudden death, previous atrial fibrillation, and anterior …
A large study found that family history of sudden death, past atrial fibrillation, and front heart attacks increase the chance of dangerous …
May 2, 2026
Meta-analysis finds invasive therapy reduces MI and revascularization in elderly NSTEMI patients
Cardiology Meta-analysis
Meta-analysis finds invasive therapy reduces MI and revascularization in elderly NSTEMI patients Older Heart Attack Patients Do Better With Stents But Face Bleeding Risks
This systematic review and meta-analysis of 2997 elderly patients with NSTEMI found that invasive therapies, compared with medical therapy, …
New data shows stents help older heart attack patients avoid repeat events but do not lower overall death rates compared to medicine alone.
May 1, 2026
Rescue PCI after failed fibrinolysis linked to worse outcomes in STEMI compared to scheduled angiography
Cardiology RCT
Rescue PCI after failed fibrinolysis linked to worse outcomes in STEMI compared to scheduled angiography Rescue PCI after failed clot-busting drugs caused worse heart outcomes than planned angiography
This pre-specified analysis of the STREAM-2 RCT compared rescue PCI after failed fibrinolysis with scheduled angiography in 583 patients wit…
Patients needing emergency heart catheterization after clot-busting drugs fared worse than those who received planned procedures, with highe…
Apr 29, 2026
Sirolimus-eluting iron bioresorbable scaffold shows higher late lumen loss than everolimus-eluting stents in coronary artery disease patients
Cardiology RCT
Sirolimus-eluting iron bioresorbable scaffold shows higher late lumen loss than everolimus-eluting stents in coronary artery disease patients New iron scaffold matches metal stents for heart artery repair
This randomized trial enrolled 518 patients with myocardial ischemia and 1 or 2 de novo target lesions at 36 centers in China.
A new iron heart scaffold matches metal stents in safety and effectiveness while dissolving over time.
Apr 29, 2026

Questions about Myocardial Infarction

Will a special breathing machine help if I have sleep problems after my heart attack?

Yes, a special breathing machine (ASVmv) can reduce nighttime oxygen drops in heart attack patients with sleep-disordered breathing, but it's not a standard treatment for all sleep problems after a heart attack.

Full answer →
Can I choose between moderate or high-intensity exercise to recover from my heart attack?

Both moderate and high-intensity exercise similarly improve heart function after a heart attack, but you should start with moderate intensity and get your doctor's approval before increasing intensity.

Full answer →
Does my kidney number creatinine level affect my risk after a heart attack procedure?

Yes, higher creatinine levels are linked to a greater risk of adverse events after a heart attack procedure, especially if you also have anemia.

Full answer →
How do artificial intelligence tools compare to doctors for predicting heart attack biomarkers?

AI tools can match or slightly outperform doctors in predicting heart attack biomarkers, but most studies lack real-world validation.

Full answer →
Do beta-blockers reduce my risk of death if my heart function is normal after MI?

For patients with normal heart function after MI, beta-blockers do not appear to reduce the risk of death or recurrent heart attack based on recent large trials.

Full answer →
Does having a specific type of myocardial injury increase my risk of future heart events?

Yes, the type of myocardial injury matters: type 1 MI carries the highest risk of future heart events, but type 2 MI and acute/chronic myocardial injury also increase risk compared to no injury.

Full answer →
See all 6 questions about Myocardial Infarction →

All Myocardial Infarction Articles